- Home
- AIXI vs STTK Comparison
AIXI vs STTK Comparison
Compare AIXI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIXI
- STTK
- Stock Information
- Founded
- AIXI 2001
- STTK 2016
- Country
- AIXI China
- STTK United States
- Employees
- AIXI N/A
- STTK N/A
- Industry
- AIXI Computer Software: Prepackaged Software
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AIXI Technology
- STTK Health Care
- Exchange
- AIXI Nasdaq
- STTK Nasdaq
- Market Cap
- AIXI 61.2M
- STTK 54.4M
- IPO Year
- AIXI 2023
- STTK 2020
- Fundamental
- Price
- AIXI $4.96
- STTK $1.16
- Analyst Decision
- AIXI
- STTK Hold
- Analyst Count
- AIXI 0
- STTK 3
- Target Price
- AIXI N/A
- STTK $2.00
- AVG Volume (30 Days)
- AIXI 96.2K
- STTK 332.9K
- Earning Date
- AIXI 12-24-2024
- STTK 11-14-2024
- Dividend Yield
- AIXI N/A
- STTK N/A
- EPS Growth
- AIXI N/A
- STTK N/A
- EPS
- AIXI N/A
- STTK N/A
- Revenue
- AIXI $65,643,604.00
- STTK $6,435,000.00
- Revenue This Year
- AIXI $22.85
- STTK $313.04
- Revenue Next Year
- AIXI $22.70
- STTK N/A
- P/E Ratio
- AIXI N/A
- STTK N/A
- Revenue Growth
- AIXI 6.22
- STTK 382.75
- 52 Week Low
- AIXI $2.06
- STTK $0.94
- 52 Week High
- AIXI $22.05
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- AIXI 43.93
- STTK 44.02
- Support Level
- AIXI $5.34
- STTK $1.07
- Resistance Level
- AIXI $6.46
- STTK $1.38
- Average True Range (ATR)
- AIXI 0.48
- STTK 0.12
- MACD
- AIXI -0.09
- STTK 0.01
- Stochastic Oscillator
- AIXI 0.00
- STTK 27.88
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.